-
公开(公告)号：US20100130490A1
公开(公告)日：2010-05-27
申请号：US12451326
申请日：2008-05-20
Applicant: Simon C. Ng , Keith B. Pfister , Martin Sendzik , James Sutton , Allan S. Wagman , Marion Wiesmann
Inventor： Simon C. Ng , Keith B. Pfister , Martin Sendzik , James Sutton , Allan S. Wagman , Marion Wiesmann
IPC: A61K31/428 , C12N5/00 , A61K31/5377 , A61K31/501 , A61K31/497 , A61K31/519 , A61K31/517 , A61K31/506 , A61K31/4439 , C07D417/12 , C07D487/04 , C07D417/14 , C07D277/82 , A61P35/00 , A61P19/10 , A61P19/02 , A61P13/00
CPC classification number: C07D413/12 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04
Abstract: Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.
Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其氧化物，酯，前药，溶剂合物及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF 1R。
-
公开(公告)号：US20070293540A1
公开(公告)日：2007-12-20
申请号：US11830686
申请日：2007-07-30
Applicant: Erik Verner , Martin Sendzik , Chitra Baskaran , Joseph Buggy , James Robinson
Inventor： Erik Verner , Martin Sendzik , Chitra Baskaran , Joseph Buggy , James Robinson
IPC: A61K31/195 , A61K31/34 , A61K31/38 , A61K31/445 , A61P35/00 , C07C259/04 , C07D307/78 , C07D333/52 , C07D405/02
CPC classification number: A61K31/343 , A61K31/18 , A61K31/33 , A61K31/34 , A61K31/4015 , A61K31/4415 , A61K41/00 , A61K45/06 , A61N5/10 , C07C259/10 , C07C2601/02 , C07D207/12 , C07D207/327 , C07D207/34 , C07D209/08 , C07D209/18 , C07D209/42 , C07D209/44 , C07D211/46 , C07D213/56 , C07D213/74 , C07D213/81 , C07D213/82 , C07D215/08 , C07D215/18 , C07D215/48 , C07D215/54 , C07D217/04 , C07D217/06 , C07D217/26 , C07D231/56 , C07D235/06 , C07D235/24 , C07D241/52 , C07D249/18 , C07D261/18 , C07D263/58 , C07D277/30 , C07D277/42 , C07D277/56 , C07D277/68 , C07D307/54 , C07D307/68 , C07D307/79 , C07D307/81 , C07D307/85 , C07D307/86 , C07D317/60 , C07D333/16 , C07D333/24 , C07D333/28 , C07D333/38 , C07D333/70 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/04 , C07D417/12 , A61K2300/00
Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract translation: 本发明涉及可用于治疗丙型肝炎的某些异羟肟酸衍生物。这些化合物也是组蛋白脱乙酰酶的抑制剂，因此可用于治疗与组蛋白脱乙酰酶活性相关的疾病。 还公开了制备这些化合物的药物组合物和方法。
-
公开(公告)号：US10308660B2
公开(公告)日：2019-06-04
申请号：US15736989
申请日：2016-06-15
Applicant: Zhuoliang Chen , Jorge Garcia Fortanet , Matthew J. LaMarche , Martin Sendzik , Victoriano Tamez, Jr. , Bing Yu
Inventor： Zhuoliang Chen , Jorge Garcia Fortanet , Matthew J. LaMarche , Martin Sendzik , Victoriano Tamez, Jr. , Bing Yu
IPC: C07D401/04 , C07D491/107 , C07D401/14 , A61P35/00
Abstract: The present invention relates to compounds of formula I: in which X1, X2, X3, Y1, Y2, Y3, R1, R2, R3a, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
公开(公告)号：US10077276B2
公开(公告)日：2018-09-18
申请号：US15110511
申请日：2015-01-16
Applicant: Christine Hiu-Tung Chen , Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Troy Douglas Smith , Sarah Williams , John William Giraldes , Martin Sendzik , Bakary-Barry Toure
Inventor： Christine Hiu-Tung Chen , Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Troy Douglas Smith , Sarah Williams , John William Giraldes , Martin Sendzik , Bakary-Barry Toure
IPC: C07D498/10 , C07D241/18 , C07D241/20 , C07D401/04 , C07D403/04 , C07D471/10 , C07D491/107 , C07D495/10 , C07D401/14
Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
公开(公告)号：US20180251471A1
公开(公告)日：2018-09-06
申请号：US15736989
申请日：2016-06-15
Applicant: Zhuoliang CHEN , Jorge Garcia FORTANET , Matthew J. LAMARCHE , Martin SENDZIK , Victoriano TAMEZ, JR. , Bing YU
Inventor： Zhuoliang Chen , Jorge Garcia Fortanet , Matthew J. LaMarche , Martin Sendzik , Victoriano Tamez, JR. , Bing Yu
IPC: C07D491/107 , C07D401/14 , C07D401/04 , A61P35/00
CPC classification number: C07D491/107 , A61P35/00 , C07D401/04 , C07D401/14
Abstract: The present invention relates to compounds of formula I: in which X1, X2, X3, Y1, Y2, Y3, R1, R2, R3a, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
Patent Agency Ranking
公开(公告)号：US09938295B2
公开(公告)日：2018-04-10
申请号：US15110511
申请日：2015-01-16
Applicant: Christine Hiu-Tung Chen , Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Troy Douglas Smith , Sarah Williams , John William Giraldes , Martin Sendzik , Bakary-Barry Toure
Inventor： Christine Hiu-Tung Chen , Zhuoliang Chen , Michael Dore , Jorge Garcia Fortanet , Rajesh Karki , Mitsunori Kato , Matthew J. LaMarche , Lawrence Blas Perez , Troy Douglas Smith , Sarah Williams , John William Giraldes , Martin Sendzik , Bakary-Barry Toure
IPC: C07D498/10 , C07D241/18 , C07D241/20 , C07D401/04 , C07D401/14 , C07D403/04 , C07D471/10 , C07D491/107 , C07D495/10
Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
-
公开(公告)号：US20130210818A1
公开(公告)日：2013-08-15
申请号：US13396339
申请日：2012-02-14
Applicant: Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
Inventor： Zilin Huang , Jeff Jin , Timothy Machajewski , William R. Antonios-McCrea , Maureen McKenna , Daniel Poon , Paul A. Renhowe , Martin Sendzik , Cynthia Shafer , Aaron Smith , Yongjin Xu , Qiong Zhang , Zheng Chen
IPC: A61K31/444 , A61K31/506 , C07D403/14 , C07D405/14 , A61K31/4439 , C07D417/14 , C07D471/04 , C07D413/14 , A61K31/496 , C07D487/04 , A61K31/4985 , C07D498/04 , A61K31/5383 , A61K31/4709 , A61K31/5377 , A61P35/00 , C07D401/14
CPC classification number: A61K31/4439 , A61K31/444 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K31/5383 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D498/04 , A61K2300/00
Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
Abstract translation: 提供了新的取代的杂环化合物，含有它们的组合物，以及使用它们来抑制Raf激酶活性的方法。 新化合物和组合物可以单独使用或与至少一种另外的药物组合使用，用于治疗Raf激酶介导的病症，例如癌症。
-
公开(公告)号：US08415381B2
公开(公告)日：2013-04-09
申请号：US12843494
申请日：2010-07-26
Applicant: Paul A. Barsanti , Cheng Hu , Jeff Jin , Robert Keyes , Robert Kucejko , Xiaodong Lin , Yue Pan , Keith B. Pfister , Martin Sendzik , James Sutton , Lifeng Wan
Inventor： Paul A. Barsanti , Cheng Hu , Jeff Jin , Robert Keyes , Robert Kucejko , Xiaodong Lin , Yue Pan , Keith B. Pfister , Martin Sendzik , James Sutton , Lifeng Wan
CPC classification number: A61K31/497 , C07D213/74 , C07D241/20 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/14
Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.
Abstract translation: 本发明提供式（I）化合物及其药学上可接受的盐，对映体，立体异构体，旋转异构体，互变异构体，非对映体或其外消旋物。 还提供了治疗由CDK9介导的疾病或病症的方法。
-
公开(公告)号：US20120064032A1
公开(公告)日：2012-03-15
申请号：US13209147
申请日：2011-08-12
Applicant: Erik J. Verner , Martin Sendzik , Chitra Baskaran , Joseph J. Buggy , James Robinson
Inventor： Erik J. Verner , Martin Sendzik , Chitra Baskaran , Joseph J. Buggy , James Robinson
IPC: A61K31/166 , A61K31/381 , A61K31/4025 , A61K31/704 , A61K31/519 , A61K31/407 , A61K39/395 , A61K31/513 , A61K31/522 , A61K33/24 , A61K38/50 , A61K38/21 , A61K38/20 , A61P35/00 , A61P35/02 , A61K31/343
CPC classification number: A61K31/343 , A61K31/18 , A61K31/33 , A61K31/34 , A61K31/4015 , A61K31/4415 , A61K41/00 , A61K45/06 , A61N5/10 , C07C259/10 , C07C2601/02 , C07D207/12 , C07D207/327 , C07D207/34 , C07D209/08 , C07D209/18 , C07D209/42 , C07D209/44 , C07D211/46 , C07D213/56 , C07D213/74 , C07D213/81 , C07D213/82 , C07D215/08 , C07D215/18 , C07D215/48 , C07D215/54 , C07D217/04 , C07D217/06 , C07D217/26 , C07D231/56 , C07D235/06 , C07D235/24 , C07D241/52 , C07D249/18 , C07D261/18 , C07D263/58 , C07D277/30 , C07D277/42 , C07D277/56 , C07D277/68 , C07D307/54 , C07D307/68 , C07D307/79 , C07D307/81 , C07D307/85 , C07D307/86 , C07D317/60 , C07D333/16 , C07D333/24 , C07D333/28 , C07D333/38 , C07D333/70 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/04 , C07D417/12 , A61K2300/00
Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract translation: 本发明涉及可用于治疗丙型肝炎的某些异羟肟酸衍生物。这些化合物也是组蛋白脱乙酰酶的抑制剂，因此可用于治疗与组蛋白脱乙酰酶活性相关的疾病。 还公开了制备这些化合物的药物组合物和方法。
-
公开(公告)号：US20110021528A1
公开(公告)日：2011-01-27
申请号：US12896535
申请日：2010-10-01
Applicant: Erik J. Verner , Martin Sendzik , Chitra Baskaran , Joseph J. Buggy , James Robinson
Inventor： Erik J. Verner , Martin Sendzik , Chitra Baskaran , Joseph J. Buggy , James Robinson
IPC: A61K31/166 , C07C237/42 , C07D209/18 , C07D333/38 , C07D213/82 , C07D215/48 , C07D277/56 , C07D213/56 , C07D207/327 , C07D217/16 , C07D401/04 , C07D241/44 , C07D295/185 , C07D417/06 , C07D405/12 , C07D307/85 , C07D405/06 , A61K31/404 , A61K31/381 , A61K31/465 , A61K31/47 , A61K31/426 , A61K31/4406 , A61K31/402 , A61K31/496 , A61K31/472 , A61K31/498 , A61K31/5375 , A61K31/5377 , A61K31/4025 , A61K31/343 , C07C233/69 , A61K31/195 , A61K31/24 , C07C231/02 , A61P35/00 , A61P35/02
CPC classification number: A61K31/343 , A61K31/18 , A61K31/33 , A61K31/34 , A61K31/4015 , A61K31/4415 , A61K41/00 , A61K45/06 , A61N5/10 , C07C259/10 , C07C2601/02 , C07D207/12 , C07D207/327 , C07D207/34 , C07D209/08 , C07D209/18 , C07D209/42 , C07D209/44 , C07D211/46 , C07D213/56 , C07D213/74 , C07D213/81 , C07D213/82 , C07D215/08 , C07D215/18 , C07D215/48 , C07D215/54 , C07D217/04 , C07D217/06 , C07D217/26 , C07D231/56 , C07D235/06 , C07D235/24 , C07D241/52 , C07D249/18 , C07D261/18 , C07D263/58 , C07D277/30 , C07D277/42 , C07D277/56 , C07D277/68 , C07D307/54 , C07D307/68 , C07D307/79 , C07D307/81 , C07D307/85 , C07D307/86 , C07D317/60 , C07D333/16 , C07D333/24 , C07D333/28 , C07D333/38 , C07D333/70 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/12 , C07D417/04 , C07D417/12 , A61K2300/00
Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
Abstract translation: 本发明涉及可用于治疗丙型肝炎的某些异羟肟酸衍生物。这些化合物也是组蛋白脱乙酰酶的抑制剂，因此可用于治疗与组蛋白脱乙酰酶活性相关的疾病。 还公开了制备这些化合物的药物组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
45
records
(took 0.05 seconds)
